MANUFACTURING

Facility

ECI’s manufacturing facility includes controlled areas for hormonal, high-potency/microdose and ODT products.

State-of-the-Art cGMP Manufacturing Facility:

  • 65,000+ sq. ft. facility
  • Site is FDA, DEA, and DOH/DBPRS compliant
  • Manufacturing, QC lab, R&D manufacturing, R&D analytical testing, clinical packaging, warehouse
  • Licenses (includes Schedules I-V)
    — FDA registration (twice inspected and approved)
    — DEA licenses (Manufacturing, Import, Export & Wholesale)
    — State licenses (Manufacturing and Wholesale)

Manufacturing Facility

ECI’s manufacturing facility includes controlled areas for hormonal, high-potency/microdose and ODT products.

State-of-the-Art cGMP Manufacturing Facility:

  • 20,000+ sq. ft. facility
  • Site is FDA, DEA, and DOH/DBPRS compliant
  • Manufacturing, QC lab, R&D manufacturing, R&D analytical testing, clinical packaging, warehouse
  • Licenses (includes Schedules I-V)
    — FDA registration (twice inspected and approved)
    — DEA licenses (Manufacturing, Import, Export & Wholesale)
    — State licenses (Manufacturing and Wholesale)

Capabilities

ECI Pharmaceuticals offers a broad range of U.S.-based manufacturing capabilities that allow for the processing of a variety of solid and liquid oral dosage forms.

  • Tablets, capsules, powders, and oral solutions requiring degrees of high-shear granulation, fluid-bed processing, bi-layers, and film coating.
  • Immediate release, extended release, hormone containment, cytotoxic containment, and ODT technology products.